This study systematically evaluated the immunogenicity and protective efficacy of two mRNA platforms in tuberculosis vaccine development, revealing a correlation between CD8+ T cell memory precursor phenotypes and protective outcomes. It provides critical insights for optimizing T cell immune responses in vaccine design, offering significant guidance for tuberculosis prevention strategies.
Literature Overview
The article titled 'mRNA-based tuberculosis vaccines BNT164a1 and BNT164b1 are immunogenic, well tolerated and efficacious in rodent models', published in Nature Immunology, systematically investigates the immunogenicity, safety, and protective efficacy of two mRNA-based tuberculosis vaccine candidates, BNT164a1 and BNT164b1, in multiple mouse models. By comparing multivalent antigen design, different mRNA chemical modification platforms, and validating results through aerosol infection models, the study demonstrates the potential of these vaccines in eliciting broad T cell and antibody responses, providing a solid preclinical foundation for next-generation tuberculosis vaccine development.Background Knowledge
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains the leading cause of death from a single infectious agent, resulting in approximately 1.23 million deaths in 2024. The only currently approved vaccine, Bacillus Calmette-Guérin (BCG), offers limited protection against pulmonary TB in adults and is unsuitable for immunocompromised individuals, failing to block the primary transmission routes. There is an urgent need for safe, effective, and long-lasting novel vaccines.
Current vaccine development faces multiple challenges: a lack of definitive correlates of protection. Although factors such as CD4+ TH1 cells, IFNγ, and TNF are associated with protection, they are insufficient to fully predict immune efficacy. Mtb antigens are highly heterogeneous, with different antigens expressed during various stages of infection (e.g., active replication, dormancy, reactivation), making single-antigen vaccines prone to missing key immune targets. Additionally, MHC diversity leads to variable immune responses across populations, limiting vaccine breadth.
The present study addresses these limitations by employing the mRNA-LNP platform, leveraging its ability to encode multiple antigens and robustly activate CD4+ and CD8+ T cells as well as antibody responses. The multivalent vaccine was designed to include eight Mtb antigens expressed across different infection stages (Ag85A, ESAT-6, Hrp1, RpfD, RpfA, HbhA, M72, VapB47). By comparing unmodified RNA (uRNA) with N1-methylpseudouridine-modified RNA (modRNA) platforms, the study explores differences in immunogenicity and safety, aiming to overcome existing vaccine shortcomings.
Research Methods and Experiments
The study utilized C57BL/6, BALB/c, and HLA-A2.1/DR1 humanized mouse models to evaluate the immunogenicity of BNT164a1 (uRNA) and BNT164b1 (modRNA). Mice received prime-boost immunizations via intramuscular injection, followed by assessment of antigen-specific IFNγ secretion by splenic T cells (ELISpot) and IgG antibody levels (ELISA). A Good Laboratory Practice (GLP)-compliant repeat-dose toxicity study was conducted in Wistar Han rats to assess safety.
Protective efficacy was evaluated using a low-dose aerosol infection model with two Mtb strains: H37Rv (lineage L4) and the highly virulent HN878 (lineage L2). Bacterial burden was measured by colony-forming units (CFU) in lungs and spleens at 30 and 60 days post-infection. Histopathological analysis and flow cytometry were used to assess lymphocyte infiltration in lung granulomas and CD8+ T cell phenotypes, particularly the proportions of memory precursor effector cells (MPEC) and long-lived memory precursor cells (LLMP).Key Conclusions and Perspectives
Research Significance and Prospects
This study validates the feasibility of multivalent mRNA vaccines for TB prevention, with their robust CD8+ T cell responses offering a new avenue to overcome BCG's limitations. Compared to traditional subunit vaccines, the mRNA platform enables easier multi-antigen expression and scalable manufacturing, providing significant translational advantages.
Although mouse models have limitations (e.g., lack of human MHC diversity, differences in antigen expression timing), the use of humanized models and challenges with multiple strains enhances the generalizability of the findings. Future studies should validate platform differences in non-human primate models and explore their application in BCG-primed booster strategies.
Conclusion
This study demonstrates the high immunogenicity and protective efficacy of mRNA vaccines BNT164a1 and BNT164b1 in tuberculosis models, with the core mechanism being the differentiation of lung-infiltrating CD8+ T cells into memory precursor phenotypes, establishing long-term immune surveillance. This finding not only provides strong vaccine candidates for TB development but also underscores the critical role of T cell memory quality in vaccine design. From bench to bedside, the scalability and flexibility of this mRNA platform support rapid iterative optimization, particularly for addressing antigenic variation or drug-resistant strains. By combining humanized animal models with multi-lineage pathogen challenges, this study establishes a rigorous preclinical evaluation framework, laying a solid foundation for upcoming clinical trials (NCT05537038, NCT05547464). In the long term, such vaccines have the potential to fill the gap left by BCG in adult pulmonary TB protection, reshaping global TB control strategies and becoming a key pillar in ending the TB epidemic.
